Abiopharma

BIOMEA FUSION, INC. (BMEA)

Symbol	BMEA
Name	BIOMEA FUSION, INC.
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: Pharmaceutical Preparations
Address	900 MIDDLEFIELD ROAD,4TH FLOOR, REDWOOD CITY, California, 94063, United States
Telephone	+1 650 980-9099
Fax	—
Email	—
Website	https://www.biomeafusion.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001840439
Description	Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The companys lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Additional info from NASDAQ: Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The companys lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.

2026-09-03 12:00

Biomea Fusion to Participate in Upcoming Investor Conferences

2026-08-24 11:00

Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

2026-08-13 11:00

Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity

2026-08-05 20:05

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

2026-06-12 20:15

Faust Elizabeth 🟢 acquired 196.3K shares (1 derivative) of Biomea Fusion, Inc. (BMEA) at $1.15 Transaction Date: Jun 10, 2026 | Filing ID: 269470

2026-06-12 20:15

AGUIAR ERIC 🟢 acquired 196.3K shares (1 derivative) of Biomea Fusion, Inc. (BMEA) at $1.15 Transaction Date: Jun 10, 2026 | Filing ID: 269469

2026-06-12 20:15

Ray Sumita 🟢 acquired 196.3K shares (1 derivative) of Biomea Fusion, Inc. (BMEA) at $1.15 Transaction Date: Jun 10, 2026 | Filing ID: 269468

2026-06-12 20:15

Averill Julianne 🟢 acquired 173.7K shares (1 derivative) of Biomea Fusion, Inc. (BMEA) at $1.15 Transaction Date: Jun 10, 2026 | Filing ID: 269465

2026-06-11 11:11

(99% Neutral) BIOMEA FUSION, INC. (BMEA) Files Form 8-K

2026-06-05 23:32

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

Trial ID	Title	Phase	Indication	Status	Start Date	Completion Date	Source
NCT07502508	Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who A…	Phase2	Type 2 Diabetes	Recruiting	2026-04-30	2027-07-01	ClinicalTrials.gov
NCT07502495	Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Ac…	Phase2	Type 2 Diabetes	Active_Not_Recruiting	2026-03-27	2027-09-01	ClinicalTrials.gov
NCT07223216	Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants	Phase1	Obesity	Active_Not_Recruiting	2025-10-23	2026-06-01	ClinicalTrials.gov
NCT07254286	Food Effect Study in Healthy Volunteers	Phase1	Healthy Volunteer	Completed	2025-09-11	2026-01-14	ClinicalTrials.gov
NCT06152042	Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus	Phase2	Type 1 Diabetes Mellitus	Completed	2023-12-28	2025-07-18	ClinicalTrials.gov
NCT05918692	A Phase 1 Study of BMF-500 in Adults With Acute Leukemia	Phase1	Acute Myeloid Leukemia	Active_Not_Recruiting	2023-07-26	2026-04-01	ClinicalTrials.gov
NCT05631574	Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven No…	Phase1	Non Small Cell Lung Cancer	Terminated	2023-01-12	2025-01-15	ClinicalTrials.gov
NCT05731544	Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Di…	Phase1	Type 2 Diabetes Mellitus	Completed	2022-08-17	2025-07-08	ClinicalTrials.gov
NCT05153330	Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (…	Phase1	Acute Myeloid Leukemia	Terminated	2022-01-24	2025-05-02	ClinicalTrials.gov

Total clinical trials: 9

Product Name	Type	Development Stage	Therapeutic Area	Study Status	Trial ID
Placebo	Other	Phase PHASE2	Type 2 Diabetes	ACTIVE_NOT_RECRUITING	NCT07502495
icovamenib 100mg	Other	Phase PHASE2	Type 2 Diabetes	ACTIVE_NOT_RECRUITING	NCT07502495
BMF-219	Other	Phase PHASE2	Type 1 Diabetes Mellitus	COMPLETED	NCT06152042
Placebo	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502495
icovamenib 100mg	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502495
Placebo	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502508
icovamenib 100 mg	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502508
BMF-219	Other	Phase PHASE2	Type 1 Diabetes Mellitus	TERMINATED	NCT06152042
BMF-219	Other	Phase PHASE2	Type 1 Diabetes Mellitus	TERMINATED	NCT06152042
BMF-219	Other	Phase PHASE2	Type 1 Diabetes Mellitus	TERMINATED	NCT06152042
BMF-219	Other	Phase PHASE2	Type 1 Diabetes Mellitus	TERMINATED	NCT06152042
BMF-219	Other	Phase PHASE2	Type 1 Diabetes Mellitus	TERMINATED	NCT06152042
BMF-219	Other	Phase PHASE2	Type 1 Diabetes Mellitus	TERMINATED	NCT06152042
BMF-219	Other	Phase PHASE2	Type 1 Diabetes Mellitus	TERMINATED	NCT06152042
BMF-219	Other	Phase PHASE2	Type 1 Diabetes Mellitus	TERMINATED	NCT06152042
Placebo	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502508
icovamenib 100 mg	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502508
Placebo	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502495
icovamenib 100mg	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502495
Placebo	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502508
icovamenib 100 mg	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502508
Placebo	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502495
icovamenib 100mg	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502495
Placebo	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502508
icovamenib 100 mg	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502508
Placebo	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502495
icovamenib 100mg	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502495
Placebo	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502508
icovamenib 100 mg	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502508
Placebo	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502495
icovamenib 100mg	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502495
Placebo	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502508
icovamenib 100 mg	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502508
Placebo	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502495
icovamenib 100mg	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502495
Placebo	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502508
icovamenib 100 mg	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502508
Placebo	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502495
icovamenib 100mg	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502495
BMF-219	Other	Phase PHASE1	Non Small Cell Lung Cancer	TERMINATED	NCT05631574
BMF-219	Other	Phase PHASE1	Acute Myeloid Leukemia	TERMINATED	NCT05153330
BMF-219	Other	Phase PHASE2	Type 1 Diabetes Mellitus	TERMINATED	NCT06152042
BMF-219	Other	Phase PHASE1	Type 2 Diabetes Mellitus	COMPLETED	NCT05731544
Icovamenib HPMC	Other	Phase PHASE1	Healthy Volunteer	COMPLETED	NCT07254286
Icovamenib	Other	Phase PHASE1	Healthy Volunteer	COMPLETED	NCT07254286
BMF-500	Other	Phase PHASE1	Acute Myeloid Leukemia	ACTIVE_NOT_RECRUITING	NCT05918692
Placebo	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502508
icovamenib 100 mg	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502508
Placebo	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502495
icovamenib 100mg	Other	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502495
BMF-650	Other	Phase PHASE1	Obesity	ACTIVE_NOT_RECRUITING	NCT07223216
icovamenib 100 mg	DRUG	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502508
Placebo	DRUG	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502495
icovamenib 100mg	DRUG	Phase PHASE2	Type 2 Diabetes	RECRUITING	NCT07502495
Icovamenib HPMC	DRUG	Phase PHASE1	Healthy Volunteer	COMPLETED	NCT07254286
Icovamenib	DRUG	Phase PHASE1	Healthy Volunteer	COMPLETED	NCT07254286
BMF-650	DRUG	Phase PHASE1	Obesity	RECRUITING	NCT07223216
BMF-500	DRUG	Phase PHASE1	Acute Myeloid Leukemia	ACTIVE_NOT_RECRUITING	NCT05918692
BMF-219	DRUG	Phase PHASE2	Type 1 Diabetes Mellitus	TERMINATED	NCT06152042

Total products: 59